share_log

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50

Benzinga ·  Jul 26, 2023 06:10

HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $44 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment